AbbVie's discounting Humira to aid Skyrizi's launch—and a price war could follow: analyst

AbbVie has big plans to grow sales for Humira follow-ups Skyrizi and upadacitinib. Early into its Skyrizi launch for psoriasis, the company has offered discounts on its megablockbuster Humira to secure favorable formulary coverage for its new drug, an analyst writes.